September 17, 2014: Roche said Wednesday that it intends to invest over $535 million on an information technology facility in Kaiseraugst, Switzerland that could employ 3,500 people by 2017.
September 17, 2014: Denmark-based Novo Nordisk has indicated it would potentially be hiring hundreds of people for R&D to work on a variety of obesity therapies. This follows closely on the U.S. FDA’s EMDC voting 14 to 1 in favor of the company’s Saxenda (liraglutide), a treatment for obesity.
September 17, 2014: Gilead's Phase II study evaluating pancreatic drug simtuzumab in combination with gemcitabine did not significantly increase progression-free survival (PFS) but said it would continue testing the drug’s efficacy treating cancer and fibrotic diseases.
September 16, 2014: Many big pharma companies are slowly shrinking when it comes to employee headcount. At the other end of the spectrum, the number of employees at big biotech firms and specialty drug makers are rapidly growing—more than offsetting the loss of jobs in big pharma.